Preview

Научно-практическая ревматология

Расширенный поиск

Применение канакинумаба при болезни Стилла взрослых

https://doi.org/10.14412/1995-4484-2018-35-40

Полный текст:

Аннотация

Болезнь Стилла у детей (системный ювенильный идиопатический артрит – ЮИА) и у взрослых (болезнь Стилла взрослых – БСВ) рассматриваются как несемейные системные аутовоспалительные заболевания неизвестной этиологии, в основе которых лежат сходные иммунопатогенетические механизмы. В основе патогенеза БСВ лежат генетически-детерминированные нарушения механизмов врожденного иммунитета, а молекулярную основу иммунопатогенеза составляют NLRP3-инфламмасома-зависимые механизмы воспаления, характеризующиеся гиперпродукцией «провоспалительных» цитокинов – интерлейкина 1 (ИЛ1) и ИЛ18. Препаратами «первой линии» лечения БСВ являются нестероидные противовоспалительные препараты, глюкокортикоиды, метотрексат и другие базисные противовоспалительные препараты, а при их недостаточной эффективности – генно-инженерные биологические препараты. Представлен обзор данных литературы, касающийся применения моноклональных антител к ИЛ1β при БСВ, свидетельствующих о хороших перспективах применения канакинумаба при этом заболевании, не только при резистентности к стандартной терапии, но и в качестве терапии «первого ряда» в дебюте болезни.

Об авторе

Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия

115522 Москва, Каширское шоссе, 34А;

кафедра ревматологии Института профессионального образования, 119991 Москва, ул. Трубецкая, 8, стр. 2



Список литературы

1. Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60. doi: 10.1177/095952879708000106

2. Bywaters EG. Still's disease in the adult. Ann Rheum Dis. 1971;30:121-33. doi: 10.1136/ard.30.2.121

3. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLOS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297

4. Peckham D, Scambler T, Savic S, McDermott MF. The burgeoning field of innate immune-mediated disease and autoinflammation. J Pathol. 2017;241:123-39. doi: 10.1002/path.4812

5. Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50. doi: 10.1186/s12969-015-0047-3

6. Efthimiou P, Moorthy LN, Mavragani CP, et al. Adult Onset Still's Disease and Autoinflammation. Int J Inflam. 2012;2012:964751. doi: 10.1155/2012/9647

7. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol. 2018;14(10):603-18. doi: 10.1038/s41584-018-0081-x

8. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22:773-92. doi: 10.1016/j.berh.2008.08.006

9. Муравьев ЮВ, Насонов ЕЛ. Болезнь Стилла, развившаяся у взрослых. Научно-практическая ревматология. 2011;49(2):58-65. doi: 10.14412/1995-4484-2011-604

10. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708-22. doi: 10.1016/j.autrev.2014.01.058

11. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. J Autoimmun. 2018 Sep;93:24-36. doi: 10.1016/j.jaut.2018.07.0

12. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19:424-30.

13. Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine. 2002;81:194-200. doi: 10.1097/00005792-200205000-00003

14. Lebrun D, Mestrallet S, Dehoux M, et al. Validation of the Fautrel classification criteria for adult-onset Still's disease. Semin Arthritis Rheum. 2018;47:578-85. doi: 10.1016/j.semarthrit.2017.07.005

15. Mitrovic S, Fautrel B. New markers for adult-onset Still's disease. Joint Bone Spine. 2018;85:285-93. doi: 10.1016/j.jbspin.2017.05.011

16. Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies. Int J Inflam. 2012;2012:879020. doi: 10.1155/2012/879020

17. Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149-59. doi: 10.1016/j.autrev.2014.08.032

18. Govoni M, Bortoluzzi A, Rossi D, Modena V. How I treat patients with adult onset Still's disease in clinical practice. Autoimmun Rev. 2017 Oct;16(10):1016-23. doi: 10.1016/j.autrev.2017.07.017

19. Mimura T, Kondo Y, Ohta A, et al. Evidence-based clinical practice guideline for adult Still's disease. Mod Rheumatol. 2018;28(5):736-57. doi: 10.1080/14397595.2018

20. Ruscitti P, Giacomelli R. Pathogenesis of adult onset still's disease: current understanding and new insights. Expert Rev Clin Immunol. 2018;14(11):965-76. doi: 10.1080/1744666X.2018.15

21. Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still's disease. Rheumatology (Oxford). 2016;55(12):2237-47. doi: 10.1093/rheumatology/kew300

22. Inoue N, Shimizu M, Tsunoda S, et al. Cytokine profile in adultonset Still's disease: Comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8-13. doi: 10.1016/j.clim.2016.05.010

23. Ichida H, Kawaguchi Y, Sugiura T, et al. Clinical manifestations of Adult-onset Still's disease presenting with erosive arthritis: Association with low levels of ferritin and Interleukin-18. Arthritis Care Res (Hoboken). 2014;66(4):642-6. doi: 10.1002/acr.22194

24. Zhou S, Qiao J, Bai J, et al. Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167-71. doi: 10.2147/TCRM.S15

25. Ruscitti P, Ursini F, Cipriani P, et al. Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13(11):1089-97. doi: 10.1080/1744666X.2017.1375853

26. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adultonset Still disease: manifestations, treatments, outcome, and prognostic factors in 57 patients. Medicine. 2014;93:91-9. doi: 10.1097/MD.0000000000000021

27. Vitale A, Insalaco A, Sfriso P, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol. 2016;7:380. doi: 10.3389/fphar.2016.00380

28. Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol. 2014;33:49-55. doi: 10.1007/s10067-013-2381-5

29. Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: A meta-analysis. Mod Rheumatol. 2018;28(5):849-57. doi: 10.1080/14397595.2017.1416924

30. Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment: A randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018 Oct 2. pii: annrheumdis-2018-213920. doi: 10.1136/annrheumdis-2018-213

31. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118-36. doi: 10.1097/00005792-199103000-00004

32. Ruscitti P, Cipriani P, Masedu F, et al. Adult onset Still's disease: evaluation of prognostic tools and validation of the systemic score, by analysis of 100 cases from three centers. BMC Med. 2016;14:194. doi: 10.1186/s12916-016-0738-8

33. Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557-67. doi: 10.1002/art.33342

34. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396-406. doi:10.1056/NEJMoa1205099

35. Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018 Sep 29. pii: annrheumdis-2018- 213150. doi: 10.1136/annrheumdis-2018-213150

36. Brunner HI, Ruperto N, Quartier P, et al. Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study [abstract]. Arthritis Rheum. 2015;67 Suppl 10:Abstract Number: 2422.

37. Grom AA, Ilowite NT, Pascual V, et al. Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Arthritis Rheum. 2016;68(1):218-28. doi: 10.1002/art.39407

38. Brunner HI, Ruperto N, Quartier P, et al. Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Follow-up Study. Arthritis Rheum. 2016;68 Suppl 10. Number: 2374.

39. Brunner HI, Ruperto N, Quartier P, et al. Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study. Arthritis Rheum. 2016;68 Suppl 10. Abstract Number: 3007.

40. Ruperto N, Brunner HI, Quartier P, et al.Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial. Ann Rheum Dis. 2016;75:401-2. doi: 10.1136/annrheumdis-2016-eular.2658

41. Ruperto N, Brunner HI, Quartier P, et al, on behalf of PRINTO/PRCSG. Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial. Ann Rheum Dis. 2016;75:265-6. doi: 10.1136/annrheumdis-2016- eular.3835

42. Horneff G, Peitz J, Kekow J, Foell D. Canakinumab for first line steroid-free treatment in a child with systemic-onset juvenile idiopathic arthritis. Scand J Rheumatol. 2017;46(6):500-1. doi: 10.1080/03009742.2017.1288827

43. Orrock JE, Ilowite NT. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2016;9(8):1015-24. doi: 10.1080/17512433.2016.1204910

44. Sun H, Van LM, Floch D, et al. Pharmacokinetics and pharmacodynamics of canakinumab in patients with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2016;56:1516-27. doi: 10.1002/jcph.754

45. Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum. 2012;42:201-5. doi: 10.1016/j.semarthrit.2012.03.004

46. Banse C, Vittecoq O, Benhamou Y, et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine. 2013;80:653-5. doi: 10.1016/j.jbspin.2013.04.011

47. Eriksson P, Jacobs C, Soderkvist P. A patient with a phenotype of adult-onset Still disease, but a genotype typical of cryopyrin-associated periodic fever syndrome. J Rheumatol. 2013;40:1632-3. doi: 10.3899/jrheum.130325

48. Barsotti S, Neri R, Iacopetti V, et al.. Successful treatment of refractory adult-onset Still disease with canakinumab: A case report. J Clin Rheumatol. 2014;20:121. doi: 10.1097/rhu.00000000000000

49. Lo Gullo A, Caruso A, Pipitone N, et al. Canakinumab in a case of adult onset Still's disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81:376-7. doi: 10.1016/j.jbspin.2013.12.011

50. Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: A nationwide survey. Orphanet J Rare Dis. 2015;10:19.

51. Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still's disease: A multicentre retrospective observational study. Front Pharmacol. 2017;8:369. doi: 10.3389/fphar.2017.00369

52. Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36:668-75.

53. Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still's disease: a pooled analysis of sjia data by age groups. Ann Rheum Dis. 2018;76(Suppl 2):395-6. doi: 10.1136/annrheumdis-2017-eular.1979

54. Sinha A, Patti R, Ambesh P, et al. Severe pulmonary hypertension due to adult-onset Still's disease. J Investig Med High Impact Case Rep. 2018;6:2324709618757260. doi: 10.1177/2324709618757260

55. Ugurlu S, Guzelant G, Yurttas B, et al. Canakinumab treatment in adult-onset Still's disease: case series. Ann Rheum Dis. 2018;76(Suppl 2):514. doi: 10.1136/annrheumdis-2018-eular.7187

56. Athanassiou P, Basdragianni D, Tzanavari A, et al. Adult Still's disease: successful treatment with canakinumab. Osteoporos Int. 2014;25:S424.

57. Galozzi P, Baggio C, Bindoli S, et al. Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease. Front Pharmacol. 2018 Sep 21;9:1074. doi: 10.3389/fphar.2018.01074

58. Junge G, Mason J, Feist E. Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017;47(2):295-302. doi: 10.1016/j.semarthrit.2017.06.006

59. Brachat AH, Grom AA, Wulffraat N, et al. Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther. 2017;19(1):13. doi: 10.1186/s13075-016-1212

60. Colafrancesco S, Priori R, Valesini G, et al. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Front Pharmacol. 2017 Jun 13;8:369. doi: 10.3389/fphar.2017.00369

61. Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: A meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345-57. doi: 10.2147/DDDT.S73428


Для цитирования:


Насонов Е.Л. Применение канакинумаба при болезни Стилла взрослых. Научно-практическая ревматология. 2018;56:35-40. https://doi.org/10.14412/1995-4484-2018-35-40

For citation:


Nasonov E.L. Therapy with canakinumab for adult-onset still's disease. Rheumatology Science and Practice. 2018;56:35-40. (In Russ.) https://doi.org/10.14412/1995-4484-2018-35-40

Просмотров: 26


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)